Incosmo S.R.L
⚠️ High Risk
FEI: 3014140682 • Biassono, Monza E della Brianza • ITALY
FEI Number
3014140682
Location
Biassono, Monza E della Brianza
Country
ITALYAddress
Via I Maggio 7, , Biassono, Monza E della Brianza, Italy
High Risk
FDA Import Risk Assessment
This firm has a significant history of FDA import refusals with notable violations.
Statistics
Score Breakdown
How is this score calculated?
Proprietary Algorithm
- 40% Violation Severity — AI-assessed (1-10)
- 30% Refusal Volume — Logarithmic scale
- 20% Recency — Decays over 5 years
- 10% Frequency — Refusals per year
© ImportRefusal.com Original Analysis
Violation Summary
NOT LISTED
It appears the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by section 510(j) or 510(k).
FRNMFGREG
The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. It appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act.
NO 510(K)
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it is a post 1976 device for which a Section 510(k)application does not appear to have been determined substantially equivalent or otherwise filed.
COL ADDED
The article appears to bear or contain, for the purpose of coloring only, a color additive which is unsafe within the meaning of Section 721(a).
UNSAFE COL
The article appears to be a color additive for the purposes of coloring only in or on drugs or devices, and is unsafe within the meaning of Section 721(a).
Refusal History
| Date | Product | Violations | Division |
|---|---|---|---|
| 5/29/2018 | 80KMJLUBRICANT, PATIENT | Division of Southeast Imports (DSEI) | |
| 4/23/2018 | 85NUCLUBRICANT, PATIENT, VAGINAL, LATEX COMPATIBLE | Division of Southeast Imports (DSEI) | |
| 4/4/2018 | 85NUCLUBRICANT, PATIENT, VAGINAL, LATEX COMPATIBLE | Division of Southeast Imports (DSEI) | |
| 3/14/2018 | 80KMJLUBRICANT, PATIENT | Division of Southeast Imports (DSEI) | |
| 3/14/2018 | 80KMJLUBRICANT, PATIENT | Division of Southeast Imports (DSEI) | |
| 3/8/2018 | 85NUCLUBRICANT, PATIENT, VAGINAL, LATEX COMPATIBLE | Division of Southeast Imports (DSEI) | |
| 3/8/2018 | 85NUCLUBRICANT, PATIENT, VAGINAL, LATEX COMPATIBLE | Division of Southeast Imports (DSEI) | |
| 3/8/2018 | 85NUCLUBRICANT, PATIENT, VAGINAL, LATEX COMPATIBLE | Division of Southeast Imports (DSEI) | |
| 3/8/2018 | 85NUCLUBRICANT, PATIENT, VAGINAL, LATEX COMPATIBLE | Division of Southeast Imports (DSEI) | |
| 3/8/2018 | 85NUCLUBRICANT, PATIENT, VAGINAL, LATEX COMPATIBLE | Division of Southeast Imports (DSEI) | |
| 3/7/2018 | 85NUCLUBRICANT, PATIENT, VAGINAL, LATEX COMPATIBLE | Division of Southeast Imports (DSEI) | |
| 3/7/2018 | 80KMJLUBRICANT, PATIENT | Division of Southeast Imports (DSEI) | |
| 3/7/2018 | 80KMJLUBRICANT, PATIENT | Division of Southeast Imports (DSEI) | |
| 3/7/2018 | 80KMJLUBRICANT, PATIENT | Division of Southeast Imports (DSEI) | |
| 3/7/2018 | 85NUCLUBRICANT, PATIENT, VAGINAL, LATEX COMPATIBLE | Division of Southeast Imports (DSEI) | |
| 3/7/2018 | 85NUCLUBRICANT, PATIENT, VAGINAL, LATEX COMPATIBLE | Division of Southeast Imports (DSEI) | |
| 3/7/2018 | 85NUCLUBRICANT, PATIENT, VAGINAL, LATEX COMPATIBLE | Division of Southeast Imports (DSEI) | |
| 3/7/2018 | 85NUCLUBRICANT, PATIENT, VAGINAL, LATEX COMPATIBLE | Division of Southeast Imports (DSEI) | |
| 3/7/2018 | 85NUCLUBRICANT, PATIENT, VAGINAL, LATEX COMPATIBLE | Division of Southeast Imports (DSEI) | |
| 3/7/2018 | 85NUCLUBRICANT, PATIENT, VAGINAL, LATEX COMPATIBLE | Division of Southeast Imports (DSEI) | |
| 3/7/2018 | 80KMJLUBRICANT, PATIENT | Division of Southeast Imports (DSEI) | |
| 3/7/2018 | 80KMJLUBRICANT, PATIENT | Division of Southeast Imports (DSEI) | |
| 3/1/2018 | 85NUCLUBRICANT, PATIENT, VAGINAL, LATEX COMPATIBLE | Division of Southeast Imports (DSEI) | |
| 3/1/2018 | 85NUCLUBRICANT, PATIENT, VAGINAL, LATEX COMPATIBLE | Division of Southeast Imports (DSEI) | |
| 3/1/2018 | 85NUCLUBRICANT, PATIENT, VAGINAL, LATEX COMPATIBLE | Division of Southeast Imports (DSEI) | |
| 3/1/2018 | 85NUCLUBRICANT, PATIENT, VAGINAL, LATEX COMPATIBLE | Division of Southeast Imports (DSEI) | |
| 3/1/2018 | 85NUCLUBRICANT, PATIENT, VAGINAL, LATEX COMPATIBLE | Division of Southeast Imports (DSEI) | |
| 3/1/2018 | 85NUCLUBRICANT, PATIENT, VAGINAL, LATEX COMPATIBLE | Division of Southeast Imports (DSEI) | |
| 3/1/2018 | 85NUCLUBRICANT, PATIENT, VAGINAL, LATEX COMPATIBLE | Division of Southeast Imports (DSEI) | |
| 3/1/2018 | 85NUCLUBRICANT, PATIENT, VAGINAL, LATEX COMPATIBLE | Division of Southeast Imports (DSEI) | |
| 2/26/2018 | 80MMSLUBRICANT, VAGINAL, PATIENT | Division of Southeast Imports (DSEI) | |
| 2/26/2018 | 80MMSLUBRICANT, VAGINAL, PATIENT | Division of Southeast Imports (DSEI) | |
| 2/1/2018 | 80KMJLUBRICANT, PATIENT | Division of Southeast Imports (DSEI) |
Frequently Asked Questions
What is Incosmo S.R.L's FDA import refusal history?
Incosmo S.R.L (FEI: 3014140682) has 33 FDA import refusal record(s) in our database, spanning from 2/1/2018 to 5/29/2018.
What is an FEI number?
FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. Incosmo S.R.L's FEI number is 3014140682.
What types of violations has Incosmo S.R.L received?
Incosmo S.R.L has been cited for 5 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.
Where does this information about Incosmo S.R.L come from?
All FDA import refusal data for Incosmo S.R.L is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.
Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.